RVL Pharmaceuticals
Joann Stavole, MS, RAC (US), serves as Vice President of Regulatory Affairs & Quality Assurance at RVL Pharmaceuticals since August 2021, following a tenure as Senior Director of Regulatory Affairs at Osmotica Pharmaceutical Corp. from December 2017 to September 2021. Prior roles include Senior Director of Regulatory Affairs at Teva Pharmaceuticals and Director of Regulatory Affairs at Actavis, where responsibilities encompassed overseeing teams and managing pre-approval activities, third-party products, and foreign site manufacturing for the US market. Joann's extensive regulatory experience began at Alpharma Pharmaceuticals as Associate Director of Regulatory Affairs. Educational qualifications include a Master of Science in Regulatory Affairs from Northeastern College of Professional Studies and a BA in English with a minor in Chemistry from Rutgers University.
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.